FDA Approval: Adjuvant Alectinib for Resected NSCLC

Episode
214
Soundcloud
Share

In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which included patients with resected stage II/III NSCLC with an ALK fusion. 

Guest
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Ben Solomon
Benjamin Solomon

PhD, MBBS, FRACP

Professor and Consultant Medical Oncologist
Peter MacCallum Cancer Center
IASLC Board of Directors